

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
Please do not report the images to the
Image Problem Mailbox.

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
11 January 2001 (11.01.2001)

PCT

(10) International Publication Number
WO 01/01851 A1

- (51) International Patent Classification⁷: A61B 5/00, A61M 39/02 (74) Agent: KOVELMAN, Paul, H.; MiniMed Inc., 12744 San Fernando Road, Sylmar, CA 91342 (US).
- (21) International Application Number: PCT/US00/13363 (81) Designated States (*national*): AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW.
- (22) International Filing Date: 15 May 2000 (15.05.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/141,935 1 July 1999 (01.07.1999) US
09/566,027 8 May 2000 (08.05.2000) US
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant: MINIMED INC. [US/US]; 12744 San Fernando Road, Sylmar, CA 91342 (US).
- Published:
— With international search report.
- (72) Inventors: VAN ANTWERP, William, P.; 26833 Pinehurst Drive, Valencia, CA 91355 (US). MASTROTARO, John, J.; 10642 Lindbrook Drive, Los Angeles, CA 90024 (US).
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: REUSABLE ANALYTE SENSOR SITE



(57) Abstract: A reusable analyte sensor site (10) for use with a replaceable analyte sensor (100) for determining a level of an analyte includes a site housing (12). Preferably, the site housing material is formed to have an interior cavity (14) with an opening and a conduit (16) that is connected to the opening of the interior cavity (14) to provide access to the interior cavity (14). The site housing material is selected to promote tissue ingrowth and vascularization, and yet be free of tissue ingress. Also, the site housing material permits the analyte to pass through the site housing material to the interior cavity (14) to permit measurement by the replaceable analyte sensor (100). In addition, the conduit (16) has a predetermined length to inhibit trauma and encapsulation of tissue occurring at the conduit (16), which is associated with placing the replaceable analyte sensor (100) in the interior cavity (14) of the site housing (12), from interfering with the tissue ingrowth and vascularization surrounding the interior cavity of the site housing material.

TITLE

Reusable Analyte Sensor Site

RELATED APPLICATIONS

- 5 This application claims priority on U.S. Provisional Application Serial No. 60/141,935 filed July 1, 1999 and entitled "Reusable Analyte Sensor Site And Method Of Using The Same", which is herein specifically incorporated by reference.

10 FIELD OF THE INVENTION

This invention relates to reusable analyte sensor sites for use with replaceable, long term implantable anlyte sensors, in particular embodiments, to reusable glucose sensor sites for use with replaceable, long term glucose sensors.

15 BACKGROUND OF THE INVENTION

- Over the years, bodily characteristics have been determined by obtaining a sample of bodily fluid. For example, diabetics often test for blood glucose levels with a blood glucose meter. Traditional blood glucose determinations have utilized a painful finger prick using a lancet to withdraw a small blood sample
- 20 that is used by the blood glucose meter. This results in discomfort from the lancet as it contacts nerves in the subcutaneous tissue. The pain of lancing and the cumulative discomfort from multiple needle pricks is a strong reason why patients fail to comply with a medical testing regimen used to determine a change in characteristic over a period of time. In addition, these blood glucose meters are
- 25 only designed to provide data at discrete points and do not provide continuous data to show the variations in the characteristic between testing times.

- A variety of subcutaneous electrochemical sensors for use with monitors have been developed for detecting and/or quantifying specific agents or compositions in a patient's blood. For instance, glucose sensors have been
- 30 developed for use in obtaining an indication of blood glucose levels in a diabetic patient. Such readings are useful in monitoring and/or adjusting a treatment regimen which typically includes the regular administration of insulin to the patient. Thus, blood glucose readings from the monitor improve medical

therapies with semi-automated medication infusion pumps of the external type, as generally described in U.S. Patent Nos. 4,562,751; 4,678,408; and 4,685,903, which are herein incorporated by reference. Typical thin film sensors are described in commonly assigned U.S. Patent Nos. 5,390,671; 5,391,250; 5,482,473; and 5,586,553 which are incorporated by reference herein. However, the thin film subcutaneous glucose sensors must be changed every few days to prevent infection. Also, due to the small size of these sensors to minimize pain on insertion under the skin, the enzyme wear out relatively quickly and require regular replacement. In addition, the user must carry around external hardware connected or linked to the sensor. Thus, although subcutaneous sensors provide an improvement over conventional test strips, they still require frequent changes.

Long term implanted glucose sensors have been proposed that can stay in the body for long periods of time, such as weeks and months. These long term implanted glucose sensors are particularly well adapted for use with automated implantable medication infusion pumps, as generally described in U.S. Patent No. 4,573,994, which is herein incorporated by reference. The long term glucose sensor would obviate the need for frequent replacement of sensors and the need to carry around a large amount of external equipment. However, the insertion and placement of long term sensors is more invasive to the body than other sensor technologies and it often causes trauma during the insertion of the long term sensor into the body. After insertion, the long term sensor would not be usable for a period of time until the body heals and vascularizes the implanted long term sensor. Thus, each time a long term sensor is replaced the body must re-vascularize the replaced sensor. Another drawback to long term sensors is the development of scar tissue that encapsulates the implanted sensor and inhibits the proper operation of the long term sensor. Therefore, materials must be carefully selected to promote vascularization and not encapsulation. This requires careful construction of the outer covering for the long term sensor, which increases costs and may further delay the period of time before a newly implanted sensor may be used.

SUMMARY OF THE DISCLOSURE

It is an object of an embodiment of the present invention to provide an improved reusable analyte sensor site, which obviates for practical purposes, the above mentioned limitations.

5 According to an embodiment of the invention, a reusable analyte sensor site for use with a replaceable analyte sensor for determining a level of an analyte includes a site housing. Preferably, the site housing material is formed to have an interior cavity with an opening and a conduit that is connected to the opening of the interior cavity to provide access to the interior cavity. The site housing
10 material is selected to promote tissue ingrowth and vascularization, and yet be free of tissue ingress. Also, the site housing material permits the analyte to pass through the site housing material to the interior cavity to permit measurement by the replaceable analyte sensor. In addition, the conduit has a predetermined length to inhibit trauma and encapsulation of tissue occurring at the conduit,
15 which is associated with placing the replaceable analyte sensor in the interior cavity of the site housing, from interfering with the tissue ingrowth and vascularization surrounding the interior cavity of the site housing material.

 In particular embodiments, the conduit has a length of at least 5 millimeters, and the site housing material has a porosity in a range from 2 to 25
20 microns. Preferably, the site housing is for implantation into sub-dermal tissue and/or inter-peritoneal tissue. Also, the site housing material is selected from a group of materials consisting essentially of Teflon and Dacron. In addition, the site housing is chosen so that it will last for a period of time such that it can be used with two or more consecutive replaceable analyte sensors.

25 Preferred embodiments utilize a site housing material that passes glucose, and the replaceable analyte sensor is a glucose sensor. In other embodiments, the invention is embodied in a system that uses a replaceable analyte sensor with the reusable analyte sensor site. In alternative embodiments, the reusable analyte sensor site may be used with a replaceable infusion catheter for infusion a fluid
30 into the body of a user.

 Other features and advantages of the invention will become apparent from the following detailed description, taken in conjunction with the accompanying drawings which illustrate, by way of example, various features of embodiments of

the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

A detailed description of embodiments of the invention will be made with
5 reference to the accompanying drawings, wherein like numerals designate
corresponding parts in the several figures.

Fig. 1 is a perspective view of a reusable analyte sensor site and sensor
monitor in accordance with an embodiment of the present invention.

Fig. 2 is a partial cross-sectional diagram of the reusable analyte sensor
10 site as shown along the line 2-2 in Fig. 1.

Fig. 3 is an enlarged cross-sectional view of the reusable sensor site as
shown within the circle 3-3 in Fig. 2.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

15 As shown in the drawings for purposes of illustration, the invention is
embodied in a reusable analyte sensor site that is used with a replaceable analyte
sensor that determines body characteristics on a continuous, intermittent or near
continuous basis. In preferred embodiments of the present invention, the
replaceable analyte sensor is for determining glucose levels in the blood and/or
20 bodily fluids of the user. However, it will be recognized that further
embodiments of the invention may be used to determine the levels of other
agents, characteristics or compositions, such as hormones, cholesterol,
medications concentrations, viral loads (e.g., HIV), or the like. The reusable
analyte sensor site and replaceable analyte sensor are primarily adapted for use in
25 sub-dermal or inter-peritoneal human tissue. However, still further embodiments
may be placed in other types tissue, such as muscle, lymph, organ tissue, veins,
arteries or the like, and used in animal tissue. In other embodiments, the reusable
analyte sensor site may be used with a medication or fluid infusion catheter that
requires regular replacement.

30 As shown in Figs. 1-3, the reusable analyte sensor site 10 in accordance
with a preferred embodiments of the present invention includes a site housing 12
that is implanted in sub-dermal or inter-peritoneal tissue 2. Initially, the
implanted site housing 12 is sutured in position by sutures (not shown).

Preferably, the sutures are absorbable by the body. However, in alternative embodiments, the sutures are permanent.

In preferred embodiments, the material of the site housing 12 is formed to create an interior cavity 14 to support an ingrown and vascularized tissue (see Figs. 2 and 3) structure around a replaceable analyte sensor 100. In addition to the interior cavity 14, the site housing 12 will form a conduit 16 that provides an entrance from the body tissue 2 to the interior cavity 14 of the site housing 12. The conduit 16 should be sized long enough so that the trauma associated with inserting and replacing the replaceable analyte sensor 100 (or catheter) will not effect the ingrown and vascularized tissue structure formed around the interior cavity 14 and an active sensing portion 102 of the replaceable analyte sensor 100 (or the outlet port of the replaceable catheter). Preferably, the length of the conduit is 5 millimeters. However, larger or smaller lengths (ranging from 2 millimeters 20 millimeters or more) may be used with the selection being dependent on the size of the site housing 12, the type of tissue 2 the site housing 12 is implanted in, the frequency within which the replaceable analyte sensor 100 (or replaceable catheter) must be replaced, or the like. Preferred embodiments of the site housing 12 can remain implanted in the tissue between 1 to 2 years. However, the actual long term life of the reusable analyte sensor site 10 will be a function of the material, the surface texture, the chemistry and the type of tissue 2 the reusable analyte sensor site 10 is implanted in. The goal is to achieve a reusable analyte sensor site 10 that is stable for multiple use to minimize the effects of frequent sensor replacement.

Preferably, the site housing 12 is formed from textured Teflon® or Dacron® that has a porosity selected to allow tissue ingrowth (i.e., cellular attachment) and vascularization of the material of the site housing 12. Many suitable materials are available from Gore & Associates Inc. and/or Baxter International. In alternative embodiments, other materials may be used, such as glass, sintered or woven metal meshes (e.g., titanium or other bio-compatible metal), composites, laminates, or the like, as long as they provide good vascularization and ingrowth of tissue. In preferred embodiments, the porosity (or mesh) size of the selected material is selected to be between 2-25 microns. However, in alternative embodiments, the porosity may be selected to be other

sizes such that cells can attach and vascularization will occur. However, the porosity (or mesh) size must be selected to inhibit tissue ingress and keep tissue cells away from the active sensing portion 102 of the replaceable analyte sensor 100. Also, the sizing must be selected to avoid, or substantially minimize

5 formation of a Fibrin sheath that attaches to the material of the site housing 12 or which causes encapsulation of the site housing 12. For example, as shown in Fig. 3, the porosity of the material of the site housing 12 is selected to promote cellular attachment of cells C to the mesh pores so as to encourage the vascularization of the site housing 12 with capillary vessels V to assure a good

10 supply of bodily fluid F in and around the active sensing portion 102 of the replaceable analyte sensor 100 (or catheter), while at the same time inhibiting the ingress of tissues and cells C.

In addition to promoting tissue ingrowth and vascularization, the material used to form the site housing 12 must be sufficiently permeable to the analyte

15 which is to be measured by the active sensing portion 102 of the replaceable analyte sensor 100. For instance, if glucose levels are being measured, the ingrown and vascularized site housing 12 must pass glucose (and transporting fluids) from the tissue 2 to the active sensing portion 102 of the replaceable analyte sensor 100 so that the glucose levels can be measured. Alternatively, if a

20 replaceable catheter (not shown) is being used, such as for example to deliver insulin, the ingrown and vascularized site housing 12 must pass insulin out of the interior cavity 14 into the tissue 2. In particular embodiments, the material of the site housing 12 may also be selected to keep out certain materials or bodily fluid constituents that could interfere with or alter the readings of the active sensing

25 portion 102 of the replaceable analyte sensor 100. It is further preferred that the material of the site housing 12 be selected so that any by products given off by the analyte sensing reaction will pass through the vascularized site housing and removed by the body of the user. In alternative embodiments, the material of the site housing 12 will be selected to pass the analyte but to contain any materials, or

30 by products, produced by the replaceable analyte sensor 100.

As shown in Fig. 2 the interior cavity 14 of the site housing 12 is selected to be sufficiently large to accommodate the active sensing portion 102 of the replaceable analyte sensor 100 (or replaceable catheter). However, the interior

cavity 14 should not be so large that the fluid within the interior cavity 14 (i.e., passed through the vascularized site housing 12) becomes stagnant. It is important that the fluid within the interior cavity 14 change frequently to provide an accurate reading on the active sensing portion 102 of the replaceable analyte sensor 100.

In preferred embodiments of the present invention, the replaceable analyte sensor is a electrochemical sensor that uses either enzymatic or fluorescent techniques to determine the analyte level. In the illustrated embodiments, the active sensing portion 102 of the replaceable analyte sensor 100 is inserted through the conduit 16 of the site housing 12 and slid into the interior cavity 14 of the site housing 12 to take analyte level readings. A connection end 104 of the replaceable analyte sensor 100 is generally attached to an analyte monitor 200 that is implanted in the body tissues 2 of the user. Preferably, the analyte monitor 200 transmits the signal values, raw data, operational information and parameters, or the like, to an external information retrieving device (not shown) or another implanted medical device (not shown). In alternative embodiments, the analyte monitor 200 may be incorporated into an implantable medication (or fluid) delivery pump, such as discussed above. Although it is possible to have the connection end 104 of the replaceable analyte sensor 100 extend outside of the body, this approach is not preferred due to the risk of infection, irritation, the possible inconvenience of having external connections, or the like.

Once in place, the traumatized tissue 4 around the conduit entrance 22 will tend to attach and encapsulate the entrance 22 to the conduit that opens out to the body tissue 2 and the mid-portion 106 of the replaceable analyte sensor 100 that is not within the interior cavity 14 of the site housing 12. This also tends to bind the entrance 22 of the conduit 16 to the mid-portion 106 of the replaceable analyte sensor 100. However, due to the length of the conduit 16 and the distance from of the traumatized tissue 4 from the interior cavity 14, there is little, or no, trauma and encapsulation that will occur around the already established interior cavity 14 of the site housing 12. Thus, the active sensing portion 102 can begin to take readings relatively soon after implantation, stabilization and calibration of the replaceable analyte sensor 100. The entrance 22 of the conduit and the mid-portion 106 of the replaceable analyte sensor 100 that are encapsulated do not

present an issue, since they do not effect operation of the active sensing portion 102 of the replaceable analyte sensor 100. When the replaceable analyte sensor 100 is replaced, the encapsulation and tissue attachment 4 around the entrance 22 of the conduit 16 is cut to free the replaceable analyte sensor 100, after which the
5 replaceable analyte sensor 100 is withdrawn from the conduit 16 and interior cavity 14 of the site housing 12. The removal process causes trauma around the entrance 22 of the conduit 16; however, it does not traumatize the interior cavity 14, since it is located a sufficient distance away from the entrance 22 of the conduit 16 to avoid the effects of the new trauma. After removal of the old
10 replaceable analyte sensor 100, a new replaceable analyte sensor 100 is inserted through the conduit 16 and into the interior cavity 14 of the site housing 12.

As discussed preferred embodiments of the replaceable analyte sensor 100 are electrochemical in nature. For instance, the sensor may use electrodes and glucose oxidase to measure the glucose levels in the bodily fluids. Examples of
15 electrochemical sensors is shown and described in U.S. Pat. No. 5,391,250; No. 5,390,671, to Lord et al., entitled "Transcutaneous Sensor Insertion Set"; No. 5,165,407, to Wilson et al., entitled "Implantable Glucose Sensor"; and No. 4,890,620, to Gough, entitled "Two-Dimensional Diffusion Glucose Substrate Sensing Electrode", which are incorporated herein in their entireties by reference.
20 Alternative embodiments may utilize optical properties such as shown and described in U.S. Patent No. 5,605,152, to Lord et al., entitled "Optical Glucose Sensor" or fiber optic structures and/or optical/fluorescent compounds such as shown and described in U.S. Patent Application Serial No. 08/752,945 (corresponding to PCT/US96/18720), to Van Antwerp et al., entitled "Detection
25 of Biological Molecules Using Chemical Amplification and Optical Sensor", all of which are herein incorporated by reference. Other sensor technologies suitable for implantation and working with bodily fluids are acceptable for use with the reusable analyte sensor site 10.

In alternative embodiments, the replaceable analyte sensor does not need
30 to extend outside and beyond the entrance 22 of the conduit 16. For instance, the replaceable analyte sensor may be in the form of a patch that is placed inside the interior cavity 14 and integrated by light transmitted through the skin. In this situation, the entrance 22 of the conduit 16 would be capped and uncapped to

provide access to the replaceable analyte sensor and the interior cavity 14. In another alternative embodiment, the entrance 22 of the conduit 16 is covered by a pierceable septum, or the like, and analyte sensor material, such as contained in microspheres, gels, or the like, is injected through the conduit 16 into the interior
5 cavity 14, and withdrawn (if necessary) by the same route when new sensor material is to be placed into the interior cavity 14.

While the description above refers to particular embodiments of the present invention, it will be understood that many modifications may be made without departing from the spirit thereof. The accompanying claims are intended
10 to cover such modifications as would fall within the true scope and spirit of the present invention.

The presently disclosed embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims, rather than the foregoing description, and all
15 changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

WHAT IS CLAIMED IS:

1. A reusable analyte sensor site for use with a replaceable analyte sensor for determining a level of an analyte, the site comprising:
a site housing material formed to have an interior cavity with an opening
5 and a conduit that is connected to the opening of the interior cavity to provide access to the interior cavity, wherein the site housing material is selected to promote tissue ingrowth and vasuclarization and be free of tissue ingress, wherein the site housing material permits the analyte to pass through the site housing material to the interior cavity to permit measurement by the replaceable analyte
10 sensor, and wherein the conduit has a predetermined length to inhibit trauma and encapsulation of tissue occurring at the conduit, associated with placing the replaceable analyte sensor in the interior cavity of the site housing, from interfering with the tissue ingrowth and vascularization surrounding the interior cavity of the site housing material.
15
2. A site according to claim 1, wherein the conduit has a length of at least 5 millimeters.
3. A site according to claim 1, wherein the site housing material has a
20 porosity in a range from 2 to 25 microns.
4. A site according to claim 1, wherein the site housing is for implantation into sub-dermal tissue.
- 25 5. A site according to claim 1, wherein the site housing is for implantation into inter-peritoneal tissue.
6. A site according to claim 1, wherein the site housing material is selected from a group of materials consisting essentially of Teflon and Dacron.
30
7. A site according to claim 1, wherein the site housing will last for a period of time such that it can be used with two or more consecutive replaceable analyte sensors.

8. A site according to claim 1, wherein the site housing material passes glucose, and wherein the replaceable analyte sensor is a glucose sensor.
9. A system for measuring analyte in a body of a user, the system
5 comprising:
a replaceable analyte sensor for determining a level of an analyte; and
a reusable analyte sensor site made from a site housing material formed to have an interior cavity with an opening and a conduit that is connected to the opening of the interior cavity to provide access to the interior cavity, wherein the
10 site housing material is selected to promote tissue ingrowth and vasuclarization and be free of tissue ingress, wherein the site housing material permits the analyte to pass through the site housing material to the interior cavity to permit measurement by the replaceable analyte sensor, and wherein the conduit has a predetermined length to inhibit trauma and encapsulation of tissue occurring at
15 the conduit, and associated with placing the replaceable analyte sensor in the interior cavity of the site housing, from interfering with the tissue ingrowth and vascularization surrounding the interior cavity of the site housing material.
10. A system according to claim 9, wherein the conduit has a length of at least
20 5 millimeters.
11. A system according to claim 9, wherein the site housing material has a porosity in a range from 2 to 25 microns.
12. A system according to claim 9, wherein the reusable analyte sensor site is
25 for implantation into sub- dermal tissue.
13. A system according to claim 9, wherein the reusable analyte sensor site is
30 for implantation into inter-peritoneal tissue.
14. A system according to claim 9, wherein the reusable analyte sensor site housing material is selected from a group of materials consisting essentially of Teflon and Dacron.

15. A system according to claim 9, wherein the reusable analyte sensor site will last for a period of time such that it can be used with two or more consecutive replaceable analyte sensors.
- 5 16. A system according to claim 9, wherein the site housing material passes glucose, and wherein the replaceable analyte sensor is a glucose sensor.
17. A reusable infusion site for use with a replaceable infusion catheter for infusion a fluid into the body of a user, the site comprising:
- 10 a site housing material formed to have an interior cavity with an opening and a conduit that is connected to the opening of the interior cavity to provide access to the interior cavity, wherein the site housing material is selected to promote tissue ingrowth and vascularization and be free of tissue ingress, wherein the site housing material permits the fluid to pass out through the site housing
- 15 material from the interior cavity to deliver the fluid to the body of the user, and wherein the conduit has a predetermined length to prevent trauma and encapsulation of tissue occurring at the conduit, and associated with placing the replaceable infusion catheter in the interior cavity of the site housing, from interfering with the tissue ingrowth and vascularization surrounding the interior
- 20 cavity of the site housing material.
18. A site according to claim 17, wherein the conduit has a length of at least 5 millimeters.

19. A site according to claim 17, wherein the site housing material has a porosity in a range from 2 to 25 microns.
20. A site according to claim 17, wherein the site housing is for implantation
5 into sub-dermal tissue.
21. A site according to claim 17, wherein the site housing is for implantation into inter-peritoneal tissue.
- 10 22. A site according to claim 17, wherein the site housing material is selected from a group of materials consisting essentially of Teflon and Dacron.
23. A site according to claim 17, wherein the site housing will last for a period of time such that it can be used with two or more consecutive replaceable
15 infusion catheters.
24. A site according to claim 17, wherein the site housing material passes insulin, and wherein the replaceable infusion catheter is an insulin compatible delivery catheter.

20




FIG. 1

2/2




FIG. 2




FIG. 3

INTERNATIONAL SEARCH REPORT

Intern. Appl. No.

PCT/US 00/13363

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61B5/00 A61M39/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61B A61M A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	US 5 324 518 A (ORTH ET AL.) 28 June 1994 (1994-06-28) column 6, line 24 - column 9, line 25 column 11, line 34 - line 52 column 13, line 44 - line 58 figures 1,2 -/-	1,9,17 3-5,7,8, 11-13, 15,16, 19-21

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

6 September 2000

Date of mailing of the international search report

14/09/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Chen, A

INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/US 00/13363

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92 07525 A (BAXTER INTERNATIONAL INC.) 14 May 1992 (1992-05-14) page 6, line 6 - line 32 page 12, line 9 -page 13, line 23 page 26, line 28 -page 27, line 17 figures 9,10 claim 9	1,9,17
A		3,4,6,8, 11,12, 14,16, 19,20, 22-24
A	WO 97 19188 A (MINIMED INC.) 29 May 1997 (1997-05-29) cited in the application page 6, line 20 -page 8, line 23 page 15, line 7 -page 16, line 23 page 23, line 25 -page 24, line 24 figures 1-6,14	1,9,17.
A	WO 81 01794 A (ASH ET AL.) 9 July 1981 (1981-07-09) page 26, line 10 -page 30, line 17 figures 10,11	1,9,17

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. al Application No

PCT/US 00/13363

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5324518 A	28-06-1994	US 5100392 A	31-03-1992
		AT 135554 T	15-04-1996
		AU 654936 B	01-12-1994
		AU 5834590 A	18-07-1991
		CA 2070641 A	09-06-1991
		DE 69026109 D	25-04-1996
		DE 69026109 T	07-11-1996
		EP 0504140 A	23-09-1992
		JP 5501968 T	15-04-1993
		WO 9108783 A	27-06-1991
WO 9207525 A	14-05-1992	AT 138256 T	15-06-1996
		AU 645155 B	06-01-1994
		AU 8951491 A	26-05-1992
		BR 9106205 A	30-03-1993
		CA 2070816 A	01-05-1992
		CN 1063046 A	29-07-1992
		DE 69119748 D	27-06-1996
		DK 507933 T	17-06-1996
		EP 0507933 A	14-10-1992
		ES 2090364 T	16-10-1996
		FI 923023 A	29-06-1992
		GR 3020673 T	31-10-1996
		IE 75706 B	10-09-1997
		IL 99732 A	31-03-1996
		JP 5504704 T	22-07-1993
		KR 169495 B	15-01-1999
		MX 9101734 A	05-06-1992
		NO 300993 B	01-09-1997
		US 5782912 A	21-07-1998
		US 5593440 A	14-01-1997
		US 5653756 A	05-08-1997
		US 5733336 A	31-03-1998
		US 5545223 A	13-08-1996
		US 5713888 A	03-02-1998
		US 5882354 A	16-03-1999
		US 5800529 A	01-09-1998
		US 5964804 A	12-10-1999
		US 5741330 A	21-04-1998
		US 5453278 A	26-09-1995
		US 5314471 A	24-05-1994
		US 5344454 A	06-09-1994
WO 9719188 A	29-05-1997	AU 1058297 A	11-06-1997
		CA 2235738 A	29-05-1997
		EP 0862648 A	09-09-1998
		JP 2000500656 T	25-01-2000
		US 6011984 A	04-01-2000
WO 8101794 A	09-07-1981	US 4403984 A	13-09-1983
		AU 6779481 A	22-07-1981
		DE 3050155 T	15-04-1982
		DE 3070407 D	02-05-1985
		EP 0042431 A	30-12-1981
		GB 2082331 A,B	03-03-1982
		IT 1146975 B	19-11-1986
		JP 56501714 T	26-11-1981
		SE 8105081 A	27-08-1981